Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Molecular MRD detection in AML

Peter Valk • 14 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia

In this video Peter Valk, PhD, from the Erasmus University Medical Center, Rotterdam, Netherlands, discusses precision medicine in acute myeloid leukemia (AML), namely biomarkers for early detection and molecular measurable residual disease detection. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Peter Valk

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA 1:13
Molecular MRD as a prognostic marker for AML patients with mutated CEBPA
Peter Valk • 4 Sep 2024
Introducing molecular diagnostics to improve leukemia care in developing countries 2:06
Introducing molecular diagnostics to improve leukemia care in developing countries
Peter Valk • 4 Sep 2024
Future considerations for MRD in AML 1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
Distinguishing between de novo AML and secondary AML using mutational signatures 2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals